NEW YORK, Feb. 25 (UPI) -- Pfizer Inc. in New York said the trial of its pneumonia immunization in adults age 65 and older against bacterial pneumonia achieved its goals.
The Community-Acquired Pneumonia Immunization Trial in Adults, the landmark study of approximately 85,000 subjects evaluating the efficacy of Prevenar 13 -- pneumococcal polysaccharide conjugate vaccine -- in adults age 65 and older, achieved both its primary and secondary clinical objectives, Pfizer said.